Bifidobacterium longum/Lactobacillus acidophilus/Enterococcus faecalis probiotic supplement
Term · Oncology and biomedicine · MLC-T-ONC-012010
An orally bioavailable, probiotic supplement containing the microorganisms Bifidobacterium longum (B. longum), Lactobacillus acidophilus (L. acidophilus) and Enterococcus faecalis (E. faecalis), with potential immunomodulating, anti-diarrheal and mucosal protective activities. Upon oral ingestion, the naturally-occurring bacterial components in B. longum/L. acidophilus/E. faecalis probiotic supplement may improve digestion and help to maintain adequate colonization of the gastrointestinal (GI) tract by modulating the composition of the normal microflora. They produce lactic acid, hydrogen peroxide and other substances during fermentation, thereby creating an acidic environment that is unfavorable for pathogens. During colonization in the GI tract, the bacteria may also form a protective intestinal barrier, which may prevent damage to the mucosal epithelium, maintain the integrity of the epithelial barrier from potential damage by toxins and certain chemicals, and reduce the potential for attachment of pathogens. This further protects against bacterial translocation and infection. In addition, this agent may reduce the secretion of pro-inflammatory cytokines and may potentiate natural and acquired immunity. Altogether, this may increase immunity, prevent GI mucosal damage, malabsorption, inflammation, and reduce diarrhea.
| Identifier | MLC-T-ONC-012010 |
|---|---|
| Field | Oncology and biomedicine |
| Synonyms | Bifidobacterium longum/Lactobacillus acidophilus/Enterococcus faecalis supplement; B. longum/L. acidophilus/E. faecalis probiotic supplement |
| References | National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-012010",
"term": "Bifidobacterium longum/Lactobacillus acidophilus/Enterococcus faecalis probiotic supplement",
"field": "Oncology and biomedicine",
"definition": "An orally bioavailable, probiotic supplement containing the microorganisms Bifidobacterium longum (B. longum), Lactobacillus acidophilus (L. acidophilus) and Enterococcus faecalis (E. faecalis), with potential immunomodulating, anti-diarrheal and mucosal protective activities. Upon oral ingestion, the naturally-occurring bacterial components in B. longum/L. acidophilus/E. faecalis probiotic supplement may improve digestion and help to maintain adequate colonization of the gastrointestinal (GI) tract by modulating the composition of the normal microflora. They produce lactic acid, hydrogen peroxide and other substances during fermentation, thereby creating an acidic environment that is unfavorable for pathogens. During colonization in the GI tract, the bacteria may also form a protective intestinal barrier, which may prevent damage to the mucosal epithelium, maintain the integrity of the epithelial barrier from potential damage by toxins and certain chemicals, and reduce the potential for attachment of pathogens. This further protects against bacterial translocation and infection. In addition, this agent may reduce the secretion of pro-inflammatory cytokines and may potentiate natural and acquired immunity. Altogether, this may increase immunity, prevent GI mucosal damage, malabsorption, inflammation, and reduce diarrhea.",
"synonyms": [
"Bifidobacterium longum/Lactobacillus acidophilus/Enterococcus faecalis supplement",
"B. longum/L. acidophilus/E. faecalis probiotic supplement"
],
"references": [
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/bifidobacterium-longum-lactobacillus-acidophilus-enterococcus-faecalis-probiotic/"
}
Record 3,530 of 17,717 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.